Form 483

Frontida BioPharm Inc Form 483, 2011-05-20

FDA issued a Form 483 to Frontida BioPharm Inc on 2011-05-20 with 4 public-safe observations.

483· Form 483 issued4 observations

Frontida BioPharm Inc · Philadelphia, United States · Issued May 20, 2011

Overview

  • 4 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

20 May 2011
21 CFR 211.160(b)(1)

Sampling and testing procedures described

Cited by Gayle S Lawson

20 May 2011
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Gayle S Lawson

20 May 2011
21 CFR 211.192

No written record of investigation

Cited by Gayle S Lawson

20 May 2011
21 CFR 314.81(b)(1)(ii)

Failure to meet specifications

Cited by Gayle S Lawson

Inspected site

FBFrontida BioPharm IncPhiladelphia, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.160(b)(1)Cited across public-safe Form 483 observations1x
21 CFR 314.81(b)(1)(ii)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 4 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere